Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques

Nature Communications

Volumn 6, Issue , 2015, Pages

  Condello, Carlo ^a   Yuan, Peng ^a   Schain, Aaron ^a   Grutzendler, Jaime ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; CHEMOKINE RECEPTOR CX3CR1; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); CHEMOKINE RECEPTOR; COLORING AGENT; CX3CR1 PROTEIN, MOUSE; NEUROPROTECTIVE AGENT; NEUROTOXIN; PEPTIDE FRAGMENT;

BIOACCUMULATION; CELLS AND CELL COMPONENTS; GENE; GENETIC ENGINEERING; MUTATION; NERVOUS SYSTEM DISORDER; PROTEIN; RODENT; TOXIN;

AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL AGING; CELL EXPANSION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FEMALE; GENE DELETION; IMMUNOTHERAPY; IN VIVO STUDY; MALE; MICROGLIA; MOUSE; NERVE FIBER DEGENERATION; NEUROTOXICITY; NONHUMAN; AGING; ANIMAL; ASTROCYTE; BRAIN; DIFFUSION; DRUG EFFECTS; HUMAN; IMMUNIZATION; METABOLISM; NEURITE; PATHOLOGY; SOLUBILITY; STAINING;

AGING; AMYLOID; AMYLOID BETA-PEPTIDES; ANIMALS; ASTROCYTES; BRAIN; COLORING AGENTS; DIFFUSION; FEMALE; GENE DELETION; HUMANS; IMMUNIZATION; MALE; MICE; MICROGLIA; NEURITES; NEUROPROTECTIVE AGENTS; NEUROTOXINS; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; RECEPTORS, CHEMOKINE; SOLUBILITY; STAINING AND LABELING;

EID: 84937113148     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7176     Document Type: Article

References (63)

1. Bertram, L., Lill, C. M. & Tanzi, R. E. The genetics of Alzheimer disease: back to the future. Neuron 68, 270-281 (2010).
2. Masters, C. L. & Selkoe, D. J. Biochemistry of amyloid b-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006262 (2012).
3. Palop, J. J., Chin, J. & Mucke, L. A network dysfunction perspective on neurodegenerative diseases. Nature 443, 768-773 (2006).
4. Kim, J., Basak, J. M. & Holtzman, D. M. The role of apolipoprotein E in Alzheimer's disease. Neuron 63, 287-303 (2009).
5. Iadecola, C. The pathobiology of vascular dementia. Neuron 80, 844-866 (2013).
6. Zlokovic, B. V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178-201 (2008).
7. Mandrekar, S. et al. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J. Neurosci. 29, 4252-4262 (2009).
8. Guerreiro, R. et al. TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368, 117-127 (2013).
9. Jonsson, T. et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N. Engl. J. Med. 368, 107-116 (2013).
10. Ruiz, A. et al. Assessing the role of the TREM2 p. R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. Neurobiol. Aging 35, 444 e1-4 (2013).
11. Griciuc, A. et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78, 631-643 (2013).
12. Bradshaw, E. M. et al. CD33 Alzheimer's disease locus: Altered monocyte function and amyloid biology. Nat. Neurosci. 16, 848-850 (2013).
13. Davalos, D. et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 8, 752-758 (2005).
14. Hanisch, U.-K. & Kettenmann, H. Microglia: Active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 10, 1387-1394 (2007).
15. Tsai, J., Grutzendler, J., Duff, K. & Gan, W.-B. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat. Neurosci. 7, 1181-1183 (2004).
16. Nagele, R. G. et al. Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol. Aging 25, 663-674 (2004).
17. Hickman, S. E., Allison, E. K. & El Khoury, J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J. Neurosci. 28, 8354-8360 (2008).
18. Maier, M. et al. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/ macrophage phenotype in amyloid precursor protein transgenic mice. J. Neurosci. 28, 6333-6341 (2008).
19. Liu, Z., Condello, C., Schain, A., Harb, R. & Grutzendler, J. CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-b phagocytosis. J. Neurosci. 30, 17091-17101 (2010).
20. Itagaki, S., Mcgeer, P., Akiyama, H., Zhu, S. & Selkoe, D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J. Neuroimmunol. 24, 173-182 (1989).
21. Wegiel, J. & Wisniewski, H. M. The complex of microglial cells and amyloid star in three-dimensional reconstruction. Acta Neuropathol. 81, 116-124 (1990).
22. Stalder, M., Deller, T., Staufenbiel, M. & Jucker, M. 3D-reconstruction of microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid. Neurobiol. Aging 22, 427-434 (2001).
23. El Khoury, J. et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 13, 432-438 (2007).
24. Naert, G. & Rivest, S. CC chemokine receptor 2 deficiency aggravates cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 31, 6208-6220 (2011).
25. Zhu, Y. et al. CD45 deficiency drives amyloid-b peptide oligomers and neuronal loss in Alzheimer's disease mice. J. Neurosci. 31, 1355-1365 (2011).
26. Song, M. et al. TLR4 mutation reduces microglial activation, increases Abeta deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. J. Neuroinflammation 8, 92 (2011).
27. Lemere, C. A. & Masliah, E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat. Rev. Neurol. 6, 108-119 (2010).
28. Wilcock, D. M. et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation 1, 24 (2004).
29. Levites, Y. et al. Anti-Abeta42-and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J. Clin. Invest. 116, 193-201 (2006).
30. Wang, A., Das, P., Switzer, R. C., Golde, T. E. & Jankowsky, J. L. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J. Neurosci. 31, 4124-4136 (2011).
31. McGeer, E. G. & McGeer, P. L. Neuroinflammation in Alzheimer's disease and mild cognitive impairment: A field in its infancy. J. Alzheimers Dis. 19, 355-361 (2010).
32. Gandy, S. & Heppner, F. L. Microglia as dynamic and essential components of the amyloid hypothesis. Neuron 78, 575-577 (2013).
33. Yang, F. et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 5892-5901 (2005).
34. Okamura, N. et al. In vivo detection of amyloid plaques in the mouse brain using the near-infrared fluorescence probe THK-265. J. Alzheimers Dis. 23, 37-48 (2011).
35. Yanagisawa, D. et al. Curcuminoid binds to amyloid-b1-42 oligomer and fibril. J. Alzheimers Dis. 24(Suppl 2), 33-42 (2011).
36. Kayed, R. et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegener 2, 18 (2007).
37. Kayed, R. et al. Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Ab oligomers. Mol. Neurodegener. 5, 57 (2010).
38. Wogulis, M. et al. Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. J. Neurosci. 25, 1071-1080 (2005).
39. O'Nuallain, B. et al. Amyloid-protein dimers rapidly form stable synaptotoxic protofibrils. J. Neurosci. 30, 14411-14419 (2010).
40. Condello, C., Schain, A. & Grutzendler, J. Multicolor time-stamp reveals the dynamics and toxicity of amyloid deposition. Sci. Rep. 1, 19 (2011).
41. Nixon, R. A. et al. The lysosomal system in neurons. Involvement at multiple stages of Alzheimer's disease pathogenesis. Ann. N. Y. Acad. Sci. 674, 65-88 (1992).
42. Nixon, R. A. et al. Extensive involvement of autophagy in Alzheimer disease: An immuno-electron microscopy study. J. Neuropathol. Exp. Neurol. 64, 113-122 (2005).
43. Sanchez-Varo, R. et al. Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer's mice hippocampus. Acta Neuropathol. 123, 53-70 (2012).
44. Zhou, Z. et al. Crowded cell-like environment accelerates the nucleation step of amyloidogenic protein misfolding. J. Biol. Chem. 284, 30148-30158 (2009).
45. Ban, T., Yamaguchi, K. & Goto, Y. Direct observation of amyloid fibril growth, propagation, and adaptation. Acc. Chem. Res. 39, 663-670 (2006).
46. Jansen, R., Grudzielanek, S., Dzwolak, W. & Winter, R. High pressure promotes circularly shaped insulin amyloid. J. Mol. Biol. 338, 203-206 (2004).
47. Banati, R. B., Rothe, G., Valet, G. & Kreutzberg, G. W. Detection of lysosomal cysteine proteinases in microglia: flow cytometric measurement and histochemical localization of cathepsin B and L. Glia 7, 183-191 (1993).
48. Yang, C.-N. et al. Mechanism mediating oligomeric Ab clearance by näve primary microglia. Neurobiol. Dis. 42, 221-230 (2011).
49. Cohen, S. I. A. et al. Proliferation of amyloid-b42 aggregates occurs through a secondary nucleation mechanism. Proc. Natl. Acad. Sci. USA 110, 9758-9763 (2013).
50. Koole, M. et al. Whole-body biodistribution and radiation dosimetry of 18F-GE067: A radioligand for in vivo brain amyloid imaging. J. Nucl. Med. 50, 818-822 (2009).
51. Lin, K.-J. et al. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent-a pilot study. Nucl. Med. Biol. 37, 497-508 (2010).
52. Zhang, X. et al. Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid beta species in Alzheimer's disease. J. Am. Chem. Soc. 135, 16397-16409 (2013).
53. Zhang, X. et al. A bifunctional curcumin analogue for two-photon imaging and inhibiting crosslinking of amyloid beta in Alzheimer's disease. Chem. Commun. (Camb) 50, 11550-11553 (2014).
54. Kayed, R. et al. Permeabilization of lipid bilayers is a common conformationdependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 279, 46363-46366 (2004).
55. Sepulveda, F. J., Parodi, J., Peoples, R. W., Opazo, C. & Aguayo, L. G. Synaptotoxicity of Alzheimer beta amyloid can be explained by its membrane perforating property. PLoS ONE 5, e11820 (2010).
56. Yoshiike, Y., Chui, D.-H., Akagi, T., Tanaka, N. & Takashima, A. Specific compositions of amyloid-beta peptides as the determinant of toxic beta-aggregation. J. Biol. Chem. 278, 23648-23655 (2003).
57. Kuperstein, I. et al. Neurotoxicity of Alzheimer's disease Ab peptides is induced by small changes in the Ab42 to Ab40 ratio. EMBO J. 29, 3408-3420 (2010).
58. Pauwels, K. et al. Structural basis for increased toxicity of pathological ab42:ab40 ratios in Alzheimer disease. J. Biol. Chem. 287, 5650-5660 (2012).
59. Jan, A. et al. Abeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species. J. Biol. Chem. 286, 8585-8596 (2011).
60. Streit, W. J. Microglial senescence: does the brain's immune system have an expiration date? Trends Neurosci. 29, 506-510 (2006).
61. Cohen, E. et al. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 139, 1157-1169 (2009).
62. Esparza, T. J. et al. Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann. Neurol. 73, 104-119 (2013).
63. Grathwohl, S. A. et al. Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat. Neurosci. 12, 1361-1363 (2009).